

Expres²ion Biotech Holding AB: Outcome of rights issue

On 24 August 2017, the subscription period of Expres²ion Biotech Holding AB's ("Expres²ions") rights issue with a maximum of approx. SEK 3.9 million ended. The rights issue was subscribed at approx. SEK 6 million, corresponding to a subscription rate of approximately 153 percent. Through the rights issue, 872,873 new shares are issued and Expres²ion receives approx. SEK 3.9 million before the emission costs of approx. SEK 0.4 million. Settlement notes are due to be sent out today, 30 August, 2017.

Note: This is a non-certified English translation of a press release originally drafted in Swedish and published 08:32 CET, 30 August 2017. The Swedish version prevails.

CEO Dr. Steen Klysner comments

"I would like to thank all those who chose to invest in Expres²ion and it is gratifying that the interest in the company and our future plans is high. The cash injected into the company will facilitate our investment and thus our continued work with the Joint Venture company AdaptVac as well as the projects enabled by our part ownership of AdaptVac."

Subscription and assignment

The rights issue was subscribed to SEK 5,994,252 including subscription commitments, corresponding to a subscription rate of approx. 153 percent. 872,873 shares are newly issued and Expres²ion therefore receives approx. SEK 3.9 million before emission costs, which are estimated to amount to approx. SEK 0.4 million. 827,406 shares (equivalent to approx. 95 percent) are awarded to subscribers with preferential rights. Allotment has been made in accordance with the allocation principles as stated in the company's memorandum. The subscribers who receive shares without preferential rights will receive settlement notes, which are sent today, August 30, 2017. Subscribers who are not granted shares will not receive settlement notes.

Number of shares and share capital

When Expres²ion's rights issue has been registered with the Swedish Companies Registration Office, the total number of shares will amount to 9,601,612 and the share capital amounts to SEK 1,066,845.7778.

Trade with BTA

Trading in BTA (Betald Tecknad Aktie = "Paid Subscription Share") will take place on Nasdaq Stockholm First North until "Bolagsverket" has registered the rights issue. Registration is scheduled for mid-September 2017.

Financial Advisor and Certified Adviser

Sedermera Fondkommission is financial advisor for Expres²ion in relation to the rights issue. Sedermera Fondkommission is also appointed Certified Adviser for the company.

For further information regarding the rights issue, please contact:

Sedermera Fondkommission
Telephone: +46 (0) 40-615 14 10
E-mail: info@sedermera.se

For further information regarding Expres²ion, please contact:

Dr. Steen Klysner, CEO
Telephone: +45 2062 9908
E-mail: sk@expres2ionbio.com

This information is information that Expres²ion Biotech Holding AB is obliged to make public in accordance with the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above, on 30 August, 2017.

Expres²ion Biotechnologies ApS, is a fully owned Danish subsidiary of Expres²ion Biotech Holding AB with company register number 559033-3729. The subsidiary has developed a unique platform technology, Expres², enabling cost effective development and robust production of complex proteins for new vaccines and diagnostics for e.g. Malaria and Zika. Since founded in 2010, the company has used its patented Expres² platform to produce more than 250 proteins in collaborations with research institutions and biopharmaceutical companies, with a superior efficiency and success rate.